FitzroyWDawkinsMD

Oncology • Malvern, PA

Director, Clinical Research, Janssen Pharmaceutical Company

Join to view full profile

Dr. Dawkins is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dawkins' full profile

Already have an account?

Office
200 Great Valley Pkwy
Malvern, PA 19355
Phone+1 610-240-8321

Education & Training

George Washington UniversityFellowship, Hematology and Medical Oncology, 1988 - 1991
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1984

Certifications & Licensure

DC State Medical License 1990 - 2018
American Board of Internal Medicine Internal Medicine

Clinical Trials

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) Start of enrollment: 2014 Mar 01
Terminated
Phase 3
A Study of Ruxolitinib in Pancreatic Cancer Patients Start of enrollment: 2014 Jun 01
Terminated
Phase 3
A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2016 Dec 29
Completed
Phase 1, Phase 2
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib Start of enrollment: 2016 Nov 30
Active, not recruiting
Phase 2
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) Start of enrollment: 2017 Mar 02
Completed
Phase 2
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) Start of enrollment: 2017 Feb 15
Completed
Phase 1
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma Start of enrollment: 2018 Mar 14
Active, not recruiting
Phase 2
A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease Start of enrollment: 2017 Apr 20
Terminated
Phase 1
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) Start of enrollment: 2017 Dec 18
Active, not recruiting
Phase 2
A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) Start of enrollment: 2018 Aug 02
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

6 citations
HFE C282Y homozygotes aged 25-29 years at HEIRS Study initial screening.
James C. Barton, Ronald T. Acton, Catherine Leiendecker-Foster, Laura C. Lovato, Paul C. Adams
Genetic Testing. 2007-10-21
535 citations
Hemochromatosis and Iron-Overload Screening in a Racially Diverse Population
Paul C. Adams, David M. Reboussin, James C. Barton, Christine E. McLaren, John H. Eckfeldt
The New England Journal of Medicine. 2005-04-28
65 citations
Relationships of Serum Ferritin, Transferrin Saturation, and HFE Mutations and Self-Reported Diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) Study
Ronald T. Acton, James C. Barton, Leah Passmore, Paul C. Adams, Mark Speechley
Diabetes Care. 2006-09-01

Press Mentions

Forma Therapeutics : Appoints Two New Vice Presidents to Lead Key Organizational FunctionsSeptember 15th, 2020
Clinical Manifestations of Hemochromatosis in HFE C282Y Homozygotes Identified by ScreeningJuly 20th, 2019

Grant Support

HeirsNational Center For Research Resources2004

FitzroyWDawkinsMD

Dr. Dawkins is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

Viewing the full profile is available to verified healthcare professionals only.